Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
SK Hynix Overtakes Samsung as South Korea’s Most Valuable Company 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
CAMBRIDGE, Mass., Feb. 03, 2016 -- SAGE Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that Jeff Jonas, M.D., Chief Executive Officer of Sage, will present at the 2016 Leerink Global Healthcare Conference at 3:55 PM ET on Wednesday, February 10, 2016, in New York City.
A live webcast of the presentation can be accessed on the investor page of Sage's website at investor.sagerx.com. A replay of the webcast will also be archived for up to 30 days on Sage's website following the conference.
About Sage Therapeutics
Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. Sage's lead program, SAGE-547, is in Phase 3 clinical development for super-refractory status epilepticus, a rare and severe seizure disorder. Sage is developing its next generation modulators, including SAGE-217, SAGE-689 and SAGE-718, with a focus on acute and chronic CNS disorders. For more information, please visit www.sagerx.com.
Investor Contact: Paul Cox, Sage Therapeutics [email protected] 617-299-8377 Media Contact: Maureen L. Suda, Suda Communications LLC [email protected] 585-387-9248
